How much revenue does Guangdong Biolight Meditech make?

Guangdong Biolight Meditech reported 1.10 billion CNY in revenue for fiscal year 2025, up 3.3% from 1.06 billion CNY in fiscal year 2024. In Q1 2026 revenue was 242.99 million CNY.

What is Guangdong Biolight Meditech's largest business segment?

industry, with 735.36 million CNY or 70% of segment revenue in fiscal year 2024. Next: Business (30%).

Where does Guangdong Biolight Meditech make most of its revenue?

China: 76% of revenue by region in fiscal year 2024, followed by Export (24%).

What companies are similar to Guangdong Biolight Meditech?

Listed companies of a similar size in the same industry (targeted healthcare equipment) include Jiangxi Sanxin Medtec Co.,Ltd. (300453.SZ), Hangzhou AGS MedTech Co., Ltd. (688581.SS), SWS Hemodialysis Care Co., Ltd. (688410.SS), Ningbo David Medical Device Co., Ltd. (300314.SZ).

Guangdong Biolight Meditech Co., Ltd. (300246.SZ) Stock

About Guangdong Biolight Meditech Co., Ltd.

Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease. The company offers emergency and critical care monitor, subcritical care monitor, general ward monitor, outpatient monitor, neonatal monitor, infusion pump, ele...

At a glance

Guangdong Biolight Meditech reported revenue of 1.10 billion CNY for fiscal year 2025, up 3.3% from fiscal year 2024, and net income of -69.43 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 242.99 million CNY, down 1.9% from a year before. Its largest business segment, industry, brought in 70% of segment revenue in fiscal year 2024; China was the largest region with 76%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.